Skip to content

A comparative study for opioid usage after thoracoscopic radical resection of lung cancer between exposed and non-exposed smoke exposed groups

A comparative study for opioid usage after thoracoscopic radical resection of lung cancer between exposed and non-exposed smoke exposed groups

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018901
Enrollment
Unknown
Registered
2018-10-16
Start date
2018-10-10
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second-hand smoke exposure

Interventions

Second-hand smoke exposure group:opioid dosage
No second-hand smoke exposure group:opioid dosage

Sponsors

He'nan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients undergoing radical surgery for thoracoscopic lung cancer under general anesthesia; 2) 30-65 years of age; 3) BMI index 18-26 kg/m2; 4) ASA classification I to II; 5) Voluntary signature of informed consent.

Exclusion criteria

Exclusion criteria: 1. Communication barriers, inability to cooperate with researchers, such as language comprehension disorders, mental illness, etc.; 2. To identify or suspect a history of alcohol, analgesic or other substance abuse and addiction; History of chest pain, history of analgesic Drug Administration in the past 3 months, recent surgical history, and signs of acute infection; 3. Unstable angina and myocardial infarction occurred within 3 months; Heart function NYHA graded = 3; 4. Preoperative visit blood pressure = 180/110 mm Hg(WHO-ISH hypertension guide level 3 hypertension); 5. Patients with diabetes complications(diabetic ketoacidosis, hypertonic coma, various infections, large vascular lesions, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc.); 6. Severe abnormal liver and kidney function(severe abnormal liver function: ALT, AST, ALP or TBIL any of the items & GT; Normal value upper limit 2 times; Severe renal dysfunction: Cr clearance 177umol/L); 7. participated in other clinical trials within three months before being selected for the study.

Design outcomes

Primary

MeasureTime frame
Total dosage of opioids 48 hours after operation;

Secondary

MeasureTime frame
Preoperative skin electrical pain threshold;VAS score of rest and cough at 1, 6, 24 and 48 hours after operation;The number of times and effective times of PCA pressing and the total amount of remedial analgesics at 48 hours after operation.;Analgesic related adverse reactions (such as nausea, vomiting, sedation, vertigo and respiratory depression);Dosage of sufentanil and remifentanil during operation;Incidence and management of chronic pain 3 months after operation;

Countries

China

Contacts

Public ContactLI BING

He'nan People's Hospital

540026341@qq.com+86 18638637913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026